Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trial
American Journal of Hematology · 2023
DOI: 10.1002/ajh.26936 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Polyzois Makras und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens, Greece. Hauptthemen laut MEDLINE: Denosumab, Histiocytosis, Langerhans-Cell. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: Amgen.
Abstract (Originalsprache)
This phase IIb clinical trial evaluated the efficacy of a bimonthly treatment schedule (Q8W) with 4 subcutaneous doses of denosumab 120 mg among adults with Langerhans cell histiocytosis needing first-line systemic therapy for either multifocal single-system disease or multisystem disease without risk organ involvement. Two months after the last treatment administration, seven patients showed disease regression, one stable disease, one non-active disease, and one disease progression. One year after treatment, progression was evident in two patients, while the remaining exhibited either a regression (three patients) or non-active disease (five patients). No permanent sequalae developed during the study and no adverse events were adjudicated in treatment. In conclusion, four doses of denosumab 120 mg Q8W subcutaneously are an effective treatment option in Langerhans cell histiocytosis patients without risk organ involvement exhibiting a response rate of 80%. Further studies are needed to confirm its role as a disease modifying agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens, Greece.
- LCH Adult Clinic, Department of Medical Research, 251 Hellenic Air Force and VA General Hospital, Athens, Greece.
- Εndocrinology Unit, First Department of Propaedeutic and Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
- Division of Nuclear Medicine, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
- 2nd Department of Radiology, Nuclear Medicine Section, Attikon University Hospital of Athens, Chaidari, Greece.
- Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
ORCID-Profile: Polyzois Makras, Maria P Yavropoulou, Athanasios D Anastasilakis, Marina Tsoli, Gregory Kaltsas
Förderung
- Amgen
Zitieren
APA
Makras, P., Yavropoulou, M. P., Chatziioannou, S. N., Anastasilakis, A. D., Georgakopoulou, D., Tsoli, M., Chatzelis, E., & Kaltsas, G. (2023). Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trial. American Journal of Hematology. https://doi.org/10.1002/ajh.26936
Vancouver
Makras P, Yavropoulou MP, Chatziioannou SN, Anastasilakis AD, Georgakopoulou D, Tsoli M, et al. Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trial. American Journal of Hematology. 2023. doi:10.1002/ajh.26936
BibTeX
@article{Makras2023,
author = {Makras, Polyzois and Yavropoulou, Maria P and Chatziioannou, Sofia N and Anastasilakis, Athanasios D and Georgakopoulou, Danai and Tsoli, Marina and Chatzelis, Eleftherios and Kaltsas, Gregory},
title = {Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trial},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.26936}
}
EUVIMED